SkinBioTherapeutics PLC (GB:SBTX)
LSE:SBTX
Top Page
SkinBioTherapeutics
(LSE:SBTX)
Select Model
Select Model
Rating:44Neutral
Price Target:
8.50 p
â–¼(-35.85% Downside)
Action:ReiteratedDate:03/27/26
The score is held back primarily by ongoing unprofitability and weak cash flows, despite strong revenue growth and a relatively conservative balance sheet. Technicals also remain bearish with the stock trading below major moving averages and negative MACD, while valuation is constrained by losses (negative P/E) and no dividend yield support.
Positive Factors
Revenue Growth
Sustained high revenue growth indicates strong top-line momentum and customer uptake of the company’s products. Over 2-6 months this growth supports scaling prospects, strengthens negotiation leverage with partners, and provides a foundation to expand manufacturing and distribution if margins and cash conversion improve.
Negative Factors
Ongoing Unprofitability
Persistent negative EBIT and net income mean the business is not yet generating operating profits from sales. Over the next 2-6 months this limits internal reinvestment, raises dependence on external funding, and constrains the ability to scale supply chains or larger commercial initiatives without dilutive financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained high revenue growth indicates strong top-line momentum and customer uptake of the company’s products. Over 2-6 months this growth supports scaling prospects, strengthens negotiation leverage with partners, and provides a foundation to expand manufacturing and distribution if margins and cash conversion improve.
Read all positive factors
SkinBioTherapeutics (SBTX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£25.27M
Dividend YieldN/A
Average Volume (3M)673.17K
Price to Earnings (P/E)―
Beta (1Y)0.26
Revenue Growth283.74%
EPS Growth78.57%
CountryUK
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding259,168,670
10 Day Avg. Volume831,404
30 Day Avg. Volume673,172
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)4.06
Price to Sales (P/S)8.25
P/FCF Ratio-29.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)£6.20M
SkinBioTherapeutics Business Overview & Revenue Model
Company Description
SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health. The company develops SkinBiotix technology that can enhance the barrier effect of skin mo...
How the Company Makes Money
SkinBioTherapeutics’ monetisation is primarily based on commercialising its microbiome/probiotic-based skin-health technology through (a) product sales and (b) partnering/licensing-style arrangements, where available. Specifically, the company has...
SkinBioTherapeutics Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.64M | 1.21M | 132.06K | 74.76K | 0.00 |
| Gross Profit | 2.71M | 683.04K | 85.19K | 45.34K | -5.05K |
| EBITDA | -196.54K | -2.72M | -2.96M | -2.95M | -1.49M |
| Net Income | -696.25K | -2.88M | -2.84M | -2.79M | -1.43M |
Balance Sheet | |||||
| Total Assets | 12.13M | 5.22M | 2.59M | 3.08M | 5.73M |
| Cash, Cash Equivalents and Short-Term Investments | 4.78M | 800.90K | 1.31M | 1.80M | 4.61M |
| Total Debt | 993.47K | 818.74K | 100.65K | 127.86K | 139.85K |
| Total Liabilities | 2.71M | 2.25M | 599.34K | 609.61K | 519.67K |
| Stockholders Equity | 9.42M | 2.97M | 1.99M | 2.48M | 5.22M |
Cash Flow | |||||
| Free Cash Flow | -1.30M | -2.92M | -2.81M | -2.77M | -1.67M |
| Operating Cash Flow | -1.30M | -2.73M | -2.65M | -2.67M | -1.56M |
| Investing Cash Flow | -1.62M | -2.30M | -165.28K | -96.81K | -112.31K |
| Financing Cash Flow | 6.90M | 4.51M | 2.32M | -35.12K | 4.12M |
SkinBioTherapeutics Technical Analysis
Neutral
13.25
Price Trends
12.05
Negative
14.18
Negative
14.95
Negative
Market Momentum
-0.47
Negative
48.65
Neutral
76.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SBTX, the sentiment is Neutral. The current price of 13.25 is above the 20-day moving average (MA) of 9.60, above the 50-day MA of 12.05, and below the 200-day MA of 14.95, indicating a neutral trend. The MACD of -0.47 indicates Negative momentum. The RSI at 48.65 is Neutral, neither overbought nor oversold. The STOCH value of 76.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:SBTX.
SkinBioTherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | £24.35M | -1.64 | -197.54% | ― | 3.31% | 21.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | £22.82M | -3.00 | 3817.30% | ― | ― | ― | |
44 Neutral | £25.27M | -54.98 | -10.01% | ― | 283.74% | 78.57% | |
43 Neutral | £5.37M | -2.61 | -2.42% | ― | ― | ― | |
40 Underperform | £17.56M | -6.19 | -213.66% | ― | 39.88% | 81.33% | |
37 Underperform | £54.43M | -2.25 | -506.43% | ― | 63.25% | 8.94% |
* Healthcare Sector Average
GB:SBTX
SkinBioTherapeutics
9.75
-11.85
-54.86%
GB:IMM
ImmuPharma
4.54
2.04
81.60%
GB:OPTI
OptiBiotix Health
5.20
-11.05
-68.00%
GB:AREC
Arecor Therapeutics PLC
64.50
26.50
69.74%
GB:APTA
Aptamer Group Plc
0.60
0.35
140.00%
GB:OBI
Ondine Biomedical, Inc.
10.50
1.50
16.67%
SkinBioTherapeutics Corporate Events
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
SkinBioTherapeutics Faces Share Suspension as Forensic Review Delays Interim Results
Negative
Mar 20, 2026
SkinBioTherapeutics has delayed publication of its interim results for the six months to 31 December 2025 while an independent forensic review by FRP Advisory into previously disclosed matters continues. As a result, the company expects trading in...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
SkinBioTherapeutics Adds Interim CEO Rachel Parsonage to Board Amid Strategic Transition
Neutral
Mar 9, 2026
SkinBioTherapeutics, a Newcastle-based life science group specialising in skin health, builds on its proprietary SkinBiotix technology to develop cosmetic skincare and gut-skin axis supplements. Through partnerships such as Croda’s Zenakine-...
Business Operations and StrategyExecutive/Board Changes
SkinBioTherapeutics names interim CEO to steer stabilisation and renewed growth
Positive
Mar 2, 2026
SkinBioTherapeutics, a UK AIM-listed life science group specialising in skin health technologies and microbiome-based products, develops cosmetic skincare through its SkinBiotix platform and gut-skin axis supplements under the AxisBiotix brand. Th...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
SkinBioTherapeutics appoints FRP for independent forensic review
Neutral
Feb 20, 2026
SkinBioTherapeutics, which also pursues acquisitions in complementary skincare and cosmetic fields to expand distribution, geography and manufacturing, has been listed on AIM since 2017 and operates from Newcastle. The group aims to leverage its p...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
SkinBioTherapeutics Probes Ex-CEO as FY25 Royalties Reversed and Outlook Cut
Negative
Feb 16, 2026
SkinBioTherapeutics has uncovered potential misrepresentation by its former CEO that casts serious doubt on £0.77m of accrued royalty income booked in its FY25 audited accounts, and now expects to remove this income, cutting FY25 revenue to &...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
SkinBioTherapeutics CEO Resigns Amid Conduct Probe as Chair Assumes Interim Control
Negative
Feb 13, 2026
SkinBioTherapeutics plc, a life science company specialising in skin health technologies and products, develops cosmetic skincare actives through its SkinBiotix® platform and gut-skin axis food supplements under the AxisBiotix™ brand, s...
Regulatory Filings and Compliance
SkinBioTherapeutics Issues New Shares on Option Exercise, Updates Voting Rights
Neutral
Feb 11, 2026
SkinBioTherapeutics has issued 259,472 new ordinary shares following the exercise of share options granted to a former employee at the time of its IPO, with admission of the new stock to trading on AIM scheduled for 13 February 2026. The enlarged ...
Regulatory Filings and Compliance
SkinBioTherapeutics Updates Share Capital Following Option Exercises
Neutral
Jan 22, 2026
SkinBioTherapeutics plc, a UK-listed life science company specialising in skin health technologies and consumer products, has increased its total number of ordinary shares in issue to 258,909,199 following the admission of 129,736 new shares arisi...
Delistings and Listing ChangesRegulatory Filings and Compliance
SkinBioTherapeutics Issues New Shares on Option Exercise, Lifts Voting Share Count
Neutral
Jan 20, 2026
SkinBioTherapeutics has issued 129,736 new ordinary shares following the exercise of share options granted to a former employee at the time of its IPO, with admission of the new stock to trading on AIM scheduled for 22 January 2026. Following this...
Business Operations and StrategyExecutive/Board Changes
SkinBioTherapeutics Bolsters Board with New Audit Chair and CFO Promotion
Positive
Jan 5, 2026
SkinBioTherapeutics has strengthened its senior leadership team with the appointment of experienced non-executive director and audit specialist Alyson Levett as a non-executive director and Chair of the Audit Committee, and the promotion of Group ...
Business Operations and StrategyShareholder Meetings
SkinBioTherapeutics Wins Shareholder Backing for Growth and Capital Authorities at AGM
Positive
Dec 29, 2025
SkinBioTherapeutics reported that all resolutions at its Annual General Meeting were passed, including the receipt of accounts, reappointment and fee-setting authority for its auditor, and broad authorities for directors to allot shares and equity...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.